Atherosclerosis (AS), a major cardiovascular disease, is characterized by chronic inflammation and oxidative stress.
Melatonin (MLT) has emerged as a potential therapeutic agent due to its anti-inflammatory and antioxidant properties, although the specific mechanisms underlying its action, especially as far as mitochondrial function in AS is concerned, have yet to be fully elucidated.
